Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Frequently asked questions
What sector does Obsidian Therapeutics, Inc. Common Stock (OBX) operate in?
Obsidian Therapeutics, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Obsidian Therapeutics, Inc. Common Stock (OBX) current stock price?
As of the latest data, Obsidian Therapeutics, Inc. Common Stock stock price is $14.22, with a previous close of $13.86. Obsidian Therapeutics, Inc. Common Stock gained $0.36 in the last trading session, representing a 2.6% increase.
What is Obsidian Therapeutics, Inc. Common Stock (OBX) current market capitalization?
Obsidian Therapeutics, Inc. Common Stock market cap is approximately 878.41 million.
What is Obsidian Therapeutics, Inc. Common Stock (OBX) Earnings Per Share (EPS)?
The trailing EPS is -$1.63, and the forward EPS is -$2.79.
Does Obsidian Therapeutics, Inc. Common Stock (OBX) pay dividends?
No. Obsidian Therapeutics, Inc. Common Stock does not pay a dividend.
What is Obsidian Therapeutics, Inc. Common Stock (OBX) beta (volatility) score?
Obsidian Therapeutics, Inc. Common Stock has a beta of 2.641, indicating very high volatility compared to the market.
